Evidences show that blocking the immune checkpoint of PD-1 has been applied in the therapy of many human cancers clinically and experimentally, such as melanoma, non-small-cell lung cell cancer, colorectal cancer, and bladder cancer [4–7]. This evidence concerns the gene PDCD1 and colorectal cancer.